Scientia Vascular develops microfabricated neurovascular devices and currently offers a comprehensive portfolio of guidewires while also producing differentiated microcatheters and aspiration catheters. The company uses microfabrication as its platform to design tools intended to more effectively address a wide array of cerebral vasculature disease states. Scientia recently launched the Plato 17 and Socrates 38 neurovascular catheters and plans to continue commercializing next-generation neurovascular tools. The business says these technologies aim to improve patient outcomes across varied neurovascular indications. Scientia announced it raised $14 million in growth funding to accelerate that commercialization and support the next stage of its growth. An investor in the round cited the company’s strong team, differentiated technology, large market opportunity and strong financial performance. Scientia Vascular leverages a proprietary microfabrication technology platform to design, develop, and manufacture interventional medical devices from its ISO 13485 facility in Salt Lake City, Utah. Since its commercial launch in 2018, the company has introduced a portfolio of differentiated neurovascular products, including Aristotle guidewires that have been adopted at leading comprehensive and primary stroke centers. The company recently received FDA approval for its Plato® 17 microcatheter, which uses its microfabrication technology to enhance trackability, control, and stability. Scientia plans to use new financing to accelerate sales, marketing, and new product development in its core neurovascular stroke market and in adjacent peripheral vascular and interventional oncology markets. The company is positioning itself as a growing commercial platform in neurovascular surgery with an expanding product pipeline. No revenue or user metrics were disclosed in the article.

Total raised

$64M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2024